These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Partial inhibition of platelet thromboxane A2 synthesis by aspirin is associated with myonecrosis in patients with ST-segment elevation myocardial infarction. Valles J; Santos MT; Fuset MP; Moscardo A; Ruano M; Perez F; Piñon M; Breña S; Aznar J Am J Cardiol; 2007 Jan; 99(1):19-25. PubMed ID: 17196455 [TBL] [Abstract][Full Text] [Related]
12. Effect of atorvastatin on platelet thromboxane A(2) synthesis in aspirin-treated patients with acute myocardial infarction. Santos MT; Fuset MP; Ruano M; Moscardó A; Valles J Am J Cardiol; 2009 Dec; 104(12):1618-23. PubMed ID: 19962464 [TBL] [Abstract][Full Text] [Related]
13. Residual platelet reactivity in low-dose aspirin-treated patients with class 1 obesity. Lee S; Eichelberger B; Kopp CW; Panzer S; Gremmel T Vascul Pharmacol; 2021 Feb; 136():106819. PubMed ID: 33207279 [TBL] [Abstract][Full Text] [Related]
14. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy. Guthikonda S; Mangalpally K; Vaduganathan M; Patel R; Delao T; Bergeron AL; Dong JF; Lev EI; Kleiman NS Thromb Haemost; 2008 Jul; 100(1):83-9. PubMed ID: 18612542 [TBL] [Abstract][Full Text] [Related]
15. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease. Lordkipanidzé M; Pharand C; Schampaert E; Palisaitis DA; Diodati JG Int J Cardiol; 2011 Jul; 150(1):39-44. PubMed ID: 20207433 [TBL] [Abstract][Full Text] [Related]
16. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Dragani A; Pascale S; Recchiuti A; Mattoscio D; Lattanzio S; Petrucci G; Mucci L; Ferrante E; Habib A; Ranelletti FO; Ciabattoni G; Davì G; Patrono C; Rocca B Blood; 2010 Feb; 115(5):1054-61. PubMed ID: 19887674 [TBL] [Abstract][Full Text] [Related]
17. Aspirin and the in vitro linear relationship between thromboxane A2-mediated platelet aggregation and platelet production of thromboxane A2. Armstrong PC; Truss NJ; Ali FY; Dhanji AA; Vojnovic I; Zain ZN; Bishop-Bailey D; Paul-Clark MJ; Tucker AT; Mitchell JA; Warner TD J Thromb Haemost; 2008 Nov; 6(11):1933-43. PubMed ID: 18752570 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955 [TBL] [Abstract][Full Text] [Related]
19. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. Pulcinelli FM; Biasucci LM; Riondino S; Giubilato S; Leo A; Di Renzo L; Trifirò E; Mattiello T; Pitocco D; Liuzzo G; Ghirlanda G; Crea F Eur Heart J; 2009 May; 30(10):1279-86. PubMed ID: 19346231 [TBL] [Abstract][Full Text] [Related]
20. A comparison of VerifyNowR with PlateletMappingR--detected aspirin resistance and correlation with urinary thromboxane. Carroll RC; Craft RM; Snider CC; Aligeti VR; Wortham DC Anesth Analg; 2013 Feb; 116(2):282-6. PubMed ID: 23302970 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]